
    
      Phase 1b study of escalating doses of weekly subcutaneous IMO-2055 combined with fixed
      standard dose regimens of oral erlotinib (daily) and IV bevacizumab (every 3 weeks) in
      patients with previously treated advanced NSCLC.
    
  